<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wierda WG</submitter><funding>NCRR NIH HHS</funding><funding>FDA HHS</funding><funding>NCI NIH HHS</funding><pagination>1893-900</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4556366</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(11)</volume><pubmed_abstract>Ligation of CD40 on chronic lymphocytic leukemia (CLL) cells induces phenotypic and biochemical changes that facilitate CLL cell-T cell interactions and enhances the sensitivity of CLL cells to clearance by adaptive and innate immune-effector mechanisms. CLL cells can be transduced to express CD40 ligand (CD154) using a replication-defective adenovirus vector, thereby cross-linking CD40 on transduced and non-transduced, bystander CLL cells. In a previous study, patients received infusions of autologous CLL cells, transduced to express murine CD154 (mCD154), which induced anti-leukemic immune responses, but also anti-mCD154 antibodies. In this study, we report a phase I study, in which patients were infused with 1 × 10(8), 3 × 10(8) or 1 × 10(9) autologous CLL cells transduced ex vivo to ex</pubmed_abstract><journal>Leukemia</journal><pubmed_title>A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.</pubmed_title><pmcid>PMC4556366</pmcid><funding_grant_id>M01 RR000827</funding_grant_id><funding_grant_id>P01 CA081534</funding_grant_id><funding_grant_id>K08 CA106605</funding_grant_id><funding_grant_id>R01 FD003427</funding_grant_id><pubmed_authors>Jalayer A</pubmed_authors><pubmed_authors>Kipps TJ</pubmed_authors><pubmed_authors>McMannis J</pubmed_authors><pubmed_authors>Wierda WG</pubmed_authors><pubmed_authors>Castro JE</pubmed_authors><pubmed_authors>Aguillon R</pubmed_authors><pubmed_authors>Sampath D</pubmed_authors><pubmed_authors>Prussak CE</pubmed_authors><pubmed_authors>Keating M</pubmed_authors></additional><is_claimable>false</is_claimable><name>A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.</name><description>Ligation of CD40 on chronic lymphocytic leukemia (CLL) cells induces phenotypic and biochemical changes that facilitate CLL cell-T cell interactions and enhances the sensitivity of CLL cells to clearance by adaptive and innate immune-effector mechanisms. CLL cells can be transduced to express CD40 ligand (CD154) using a replication-defective adenovirus vector, thereby cross-linking CD40 on transduced and non-transduced, bystander CLL cells. In a previous study, patients received infusions of autologous CLL cells, transduced to express murine CD154 (mCD154), which induced anti-leukemic immune responses, but also anti-mCD154 antibodies. In this study, we report a phase I study, in which patients were infused with 1 × 10(8), 3 × 10(8) or 1 × 10(9) autologous CLL cells transduced ex vivo to ex</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Nov</publication><modification>2025-04-19T14:58:32.9Z</modification><creation>2019-03-27T01:57:37Z</creation></dates><accession>S-EPMC4556366</accession><cross_references><pubmed>20882050</pubmed><doi>10.1038/leu.2010.191</doi></cross_references></HashMap>